ARQT vs FOXA · rev $235.3M vs P/E 14, rev $17.13B
Arcutis Biotherapeutics Inc (ARQT) versus Fox Corp Class A (FOXA) — a side-by-side from cached financials, not a winner call.
Arcutis Biotherapeutics Inc (ARQT) is a biotechnology company listed on US.
Fox Corp Class A (FOXA) is a entertainment company listed on US.
Latest reported ARQT revenue for 2026-06-30 was $235.3M. Net income was $3.7M. ARQT currently screens at market cap $1.64B.
Latest reported FOXA revenue for 2026-06-30 was $17.13B. Net income was $1.73B. Revenue was up 5.1% from 2025-06-30 to 2026-06-30. FOXA currently screens at market cap $24.50B and trailing P/E 14.1.
ARQT currently screens at market cap $1.64B. FOXA currently screens at market cap $24.50B and trailing P/E 14.1.
Not investment advice. Open the ARQT and FOXA stock pages for the full models.
Not investment advice.